Please assess the completion status of the following clinical trial:

Trial Title: Reducing Adenoviral Patient Infected Days

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: Patients will be 18 years and older.~* Duration of pink eye symptoms: No more than 4 days in first affected eye Positive immunoassay test AdenoPlus(TM) for presence of adenovirus.~* Sex: Pink eye {adenoviral conjunctivitis (Ad-Cs)} occurs with equal prevalence in males and females, therefore we will recruit both genders.~* Race/Ethnicity: Individuals of all races and ethnicities will be invited to participate in this study. Patient recruitment will reflect the distribution of race/ethnicity demographics for the patient population specific to each study site.~Exclusion Criteria:~* Patients with history of herpes simplex infection or corneal ulceration~* Eye surgery in the last 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Betadine 5% (Type: ACTIVE_COMPARATOR): One time in-office administration (4-5 drops) of Betadine 5% limited to 2 minutes, followed by saline lavage.
- Artificial Tears (Type: PLACEBO_COMPARATOR): One time in-office administration (4-5 drops) of artificial tears limited to 2 minutes, followed by saline lavage.

Based on this trial design, predict the completion outcome and termination type (if applicable).